Avrum Gillespie, MD
Nephrology · Philadelphia, PANPI 1770747016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Vertex accounts for 85.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for nephrology clinicians in PA, where the typical reported total is $612.
Across 3 payments — averaging $47.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$122
- Bayer$21
Across 18 payments — averaging $16,433 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$265K
- AstraZeneca$29K
- Novartis$2K
What the payments were for
- Food & beverage$142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$142 in reported general payments places this provider in the 20th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 52 | $60,358 |
| AranespDarbepoetin Alfa In Polysorbat | 11 | $39,699 |
| ProcritEpoetin Alfa | 50 | $35,112 |
| VelphoroSucroferric Oxyhydroxide | 11 | $17,146 |
| TrulicityDulaglutide | 13 | $12,830 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $7,452 |
| Tacrolimus | 20 | $6,102 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,813 |
| Calcitriol | 185 | $2,391 |
| Calcium Acetate | 33 | $1,888 |
| Atomoxetine Hcl | 12 | $1,665 |
| Olmesartan Medoxomil | 69 | $1,611 |
| Mycophenolate Mofetil | 19 | $1,559 |
| SpsSodium Polystyrene Sulfon/Sorb | 15 | $1,494 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,384 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.